News | August 22, 2022
8th edition of Indo-Japanese Chronic Total Occlusion (IJCTO) summit concluded successfully
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Subscribe To Our Newsletter & Stay Updated
